Detail View

Proteomic Interrogation in Cancer Biomarker
Citations

WEB OF SCIENCE

Citations

SCOPUS

Metadata Downloads

Title
Proteomic Interrogation in Cancer Biomarker
Issued Date
2021-05
Citation
Kang, Un-Beom. (2021-05). Proteomic Interrogation in Cancer Biomarker. Advances in Experimental Medicine and Biology, 1187, 305–322. doi: 10.1007/978-981-32-9620-6_15
Type
Article
Author Keywords
CancerBiomarkerProteomicsProteogenomicsClinical application
Keywords
MASS-SPECTROMETRYPLASMA PROTEOMEPOSTTRANSLATIONAL MODIFICATIONSQUANTITATIVE-ANALYSISSUPER-SILACIDENTIFICATIONPROTEINSEXPRESSIONVALIDATIONTISSUE
ISSN
0065-2598
Abstract
Biomarkers factor into the diagnosis and treatment of almost every patient with cancer. The innovation in proteomics follows improvement of mass spectrometry techniques and data processing strategy. Recently, proteomics and typical biological studies have been the answer for clinical applications. The clinical proteomics techniques are now actively adapted to protein identification in large patient cohort, biomarker development for more sensitive and specific screening based on quantitative data. And, it is important for clinical, translational researchers to be acutely aware of the issues surrounding appropriate biomarker development, in order to facilitate entry of clinically useful biomarkers into the clinic. Here, we discuss in detail include the case research for clinical proteomics. Furthermore, we give an overview on the current developments and novel findings in proteomics-based cancer biomarker research. © Springer Nature Singapore Pte Ltd. 2021.
URI
http://hdl.handle.net/20.500.11750/15462
DOI
10.1007/978-981-32-9620-6_15
Publisher
Kluwer Academic/Plenum Publishers
Show Full Item Record

File Downloads

  • There are no files associated with this item.

공유

qrcode
공유하기

Total Views & Downloads